anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A multi-chrome cosmetic hair composition is disclosed. The composition includes a base formula suitable for hair and an interference pigment providing a colored background exhibiting interference colors that are observable at different angles of observation. The formula is sufficient to enable a homogenous suspension of the interference pigment. The formula includes a propellant, denatured alcohol, neutralized octylacrylamide/acrylates/butylaminoethyl methacrylate copolymer 4, a neutralizing agent sufficient to neutralize the octylacrylamide/acrylates/butylaminoethyl methacrylate copolymer 4 to a range of 80% to 100%, and a plasticizer. The interference pigment includes an opaque-type interference pigment consisting of particles ranging from 5 microns to 60 microns in size to fill in gaps on hair shaft surfaces and create a smooth, chrome-like effect on the hair. The interference pigment includes an inorganic layer that specularly reflects incident light and semi-transparent inorganic layers that refract the reflected light such that the interference colors are observable.
Over the years, radiotherapy has seen continual improvements and has become a standard treatment for most malignant tumors. Cardiotoxicity is a well-known radiotherapy side effect, leading to the risk of long-term morbidity and mortality in cancer survivors. Therefore, minimizing radiotherapy-related cardiotoxicity remains an important challenge in cancer care management. Indeed, multiple dose constraints were proposed for the heart and its substructures. In addition, sparing techniques were developed to reduce the exposure of the heart to ionizing radiation and are currently used in daily clinical routine. The purpose of this review is to summarize the current knowledge about radiation-induced cardiotoxicity, to discuss the previously cardiac dose constraints, and to evaluate the various management strategies.
The active ingredient in pantoprazole sodium delayed-release tablets, USP a PPI, is a substituted benzimidazole, sodium 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2- pyridinyl)methyl] sulfinyl]-1 H-benzimidazole sesquihydrate, a compound that inhibits gastric acid secretion. Its empirical formula is C 16H 14F 2N 3NaO 4S x 1.5 H 2O, with a molecular weight of 432.4. The structural formula is: 

Pantoprazole sodium, USP is a white to almost white powder and is racemic. Pantoprazole has weakly basic and acidic properties. Pantoprazole sodium sesquihydrate is freely soluble in water and practically insoluble in n-hexane.

Pantoprazole sodium, USP is supplied as delayed release tablets, available in single strength, 40 mg pantoprazole (equivalent to 45.1 mg of pantoprazole sodium USP).

Pantoprazole sodium delayed-release tablets, USP contain the following inactive ingredients: lactose monohydrate, hypromellose, crospovidone, talc, calcium stearate, povidone, propylene glycol, titanium dioxide, ferric oxide yellow, methacrylic acid and ethyl acrylate copolymer, and triethyl citrate. The tablets are imprinted with black ink containing iron oxide black, propylene glycol, and hypromellose. Pantoprazole sodium delayed-release tablets USP, 40 mg complies with USP dissolution test 3.
Monosomy 5 and deletions of the chromosome 5q (-5/del(5q)) are recurrent events in de novo adult acute myeloid leukemia (AML), reaching up to 40% of cases in secondary AML. These chromosome anomalies are associated with TP53 mutations and with very poor prognosis. Using the large Leucegene genomic and transcriptomic dataset composed of 48 -5/del(5q) patient specimens and 367 control AML, we identified DELE1 - located in the common deleted region - as the most consistently downregulated gene in these leukemias. DELE1 encodes a mitochondrial protein recently characterized as the relay of mitochondrial stress to the cytosol through a newly defined OMA1-DELE1-HRI pathway which ultimately leads to the activation of ATF4, the master transcription factor of the integrated stress response. Here, we showed that the partial loss of DELE1 expression observed in -5/del(5q) patients was sufficient to significantly reduce the sensitivity to mitochondrial stress in AML cells. Overall, our results suggest that DELE1 haploinsufficiency could represent a new driver mechanism in -5/del(5q) AML.
The dosage of levothyroxine sodium tablets for hypothyroidism or pituitary TSH suppression depends on a variety of factors including: the patient's age, body weight, cardiovascular status, concomitant medical conditions (including pregnancy), concomitant medications, coadministered food and the specific nature of the condition being treated [see Dosage and Administration (Error! Hyperlink reference not valid.), Warnings and Precautions (Error! Hyperlink reference not valid.), and Drug Interactions (Error! Hyperlink reference not valid.)]. Dosing must be individualized to account for these factors and dosage adjustments made based on periodic assessment of the patient's clinical response and laboratory parameters [see Dosage and Administration (Error! Hyperlink reference not valid.)].

For adult patients with primary hypothyroidism, titrate until the patient is clinically euthyroid and the serum TSH returns to normal [see Dosage and Administration (Error! Hyperlink reference not valid.)].

For secondary or tertiary hypothyroidism, serum TSH is not a reliable measure of levothyroxine sodium tablets dosage adequacy and should not be used to monitor therapy. Use the serum free-T4 level to titrate levothyroxine sodium tablets dosing until the patient is clinically euthyroid and the serum free-T4 level is restored to the upper half of the normal range [see Dosage and Administration (Error! Hyperlink reference not valid.)].

Inquire whether patients are taking biotin or biotin-containing supplements. If so, advise them to stop biotin supplementation at least 2 days before assessing TSH and/or T4 levels [see Dosage and Administration (2.4) and Drug Interactions (7.10)].

The peak therapeutic effect of a given dose of levothyroxine sodium tablets may not be attained for 4 to 6 weeks.
PURPOSE:To provide the titled drug preparation containing human-type angiotensin in combination with a specific stabilizing agent and useful as a hypertensive agent. CONSTITUTION:The objective human-type angiotensin agent contains (A) human- type angiotensin and (B) one or more stabilizers selected from gelatin, albumin, acidic polysaccharide (e.g. chondroitin sulfate, dextran sulfate, heparin, etc.), acidic amino acid (e.g. glutamic acid, aspartic acid, etc.) and organic acid (e.g. citric acid, lactic acid, tartaric acid, malic acid, etc.). The amounts of gelatin and albumin are preferably 1-1,000pts.wt., and the amounts of the other components are 1-500pts.wt. each per 1pt.wt. of angiotensin. EFFECT:Since the decomposition of angiotensin in the dissolved solution is suppressed and the stability of angiotensin is improved remarkably, the agent is convenient for production, treatment and storage.
The invention discloses a targeting antimicrobial peptide and a preparation method and application thereof. A sequence of the targeting antimicrobial peptide cCF10-C4 is shown in a sequence table SEQ ID No.1. The preparation method comprises the steps that enterococcus faecalis serves as a target bacterium to obtain the targeting antimicrobial peptide cCF10-C4 through design, a series of multi-structural-domain antimicrobial peptide molecules having selectivity to the enterococcus faecalis are established in a heterozygous mode. The design of a series of antimicrobial peptide molecules mainly includes two independent functional areas, namely a sterilization area and an identification area respectively. The targeting antimicrobial peptide has targeting selection capability to the target bacterium. The targeting antimicrobial peptide cCF10-C4 is conductive to reestablishment of microecological balance after treatment.
All diuretics, including ethacrynic acid, are contraindicated in anuria. If increasing electrolyte imbalance, azotemia, and/or oliguria occur during treatment of severe, progressive renal disease, the diuretic should be discontinued.

In a few patients this diuretic has produced severe, watery diarrhea. If this occurs, it should be discontinued and not used again. 

Until further experience in infants is accumulated, therapy with oral and parenteral ethacrynic acid is contraindicated.

Hypersensitivity to any component of this product.
Use of 2,5-dihydroxybenzene compounds and derivatives. The invention describes compositions and the use of 2,5-dihydroxybenzene compounds and pharmaceutically acceptable salts thereof. The invention provides methods for treating rosacea and treating psoriasis by administering a composition comprising at least one 2,5-dihydroxybenzenic compound or a pharmaceutically acceptable salt thereof and, optionally, at least one therapeutic agent. Also described are compositions comprising the administration of at least one 2,5-dihydroxybenzene compound, or a pharmaceutically acceptable salt thereof and at least one therapeutic agent. In the invention, the 2,5-dihydroxybenzenic compounds or pharmaceutically acceptable salts thereof include 2,5-dihydroxybenzenesulfonic acid esters, 2,5-dihydroxybenzoic acid esters and 2,5-dihydroxyphenylacetic acid esters. (Machine-translation by Google Translate, not legally binding)
The clinical study was parallel, controlled, and randomized with metabolic syndrome subjects (ATPIII, AHA / NHLA) aimed at the consumption of an energy-balanced balanced diet for 12 weeks and divided into two groups: Control (n = 38): dietary guidance only; and Orange Juice (n = 38): diet guidance associated with 500 mL / day of 100% whole orange juice. The recruitment process began in June 2016, the intervention was carried out from September 2016 to December 2016, and the data analysis started in January 2016. The sample number took into account variances on LDL-C, with a type I error α = 0.05 and a type II error β = 0.2 (80% power). The minimum sample size should have 32 individuals per group (n = 64). Considering an approximately 15% dropout rate, the final sample size of study was constituted by 38 individuals per group. Primary and secondary endpoints were the reduction of LDL-C and modification of the levels of cardiometabolic risk factors, inflammatory and hemodynamics parameters, respectively. Kolmogorov Smirnov and Levene test assessed normality and homogeneity of data, respectively. T-test was conducted to identify possible differences between OJ and control groups at baseline. A linear mixed-effects model was apply to determine the time effect within and between groups (Sidak post hoc) and P significance was set up ≤ 0.05. The assessment of body composition, metabolic biomarkers and food intake were analyzed over a 12-week intervention.
Participants in this correlative study (CALGB 151006) were enrolled in CALGB 80303, which was a national, multi-center, double-blind phase III study that randomly assigned patients (1:1) with advanced pancreatic cancer to gemcitabine plus bevacizumab vs gemcitabine plus placebo. Blood samples were collected from consenting participants in CALGB 80303 at the time of study registration at respective institutions and shipped to the CALGB Pathology Coordinating Office for storage (Columbus, OH).Baseline serum 25-hydroxyvitamin D (25\[OH\]D) levels were measured and examined associations between baseline 25(OH)D levels and progression-free survival and OS using the Cox rank score test.
The present application discloses a finished pharmaceutical dosage form comprising a low dose/high potency active pharmaceutical ingredient and one or more excipients. The active pharmaceutical ingredient in the present application has been blended and subsequently milled with at least one excipient before preparing the finished pharmaceutical dosage form. The disclosed finished dosage form promotes content uniformity and acceptable and reproducible dissolution rate and extent. Finished dosage forms of the present invention may comprise any active pharmaceutical ingredient; however, low solubility and/or high potency active pharmaceutical ingredients will particularly benefit. Among the low solubility and/or high potency active pharmaceutical ingredients, those with needle-like structures are even more particularly well suited for incorporation into the disclosed finished dosage forms. A finished dosage form containing ivermectin is one non-limiting example of a finished dosage form contemplated by the disclosure herein. Hormonal steroids are also particularly well suited for the invention described herein.
Study design: this study used a prospective, randomized, double-blinded, and placebo-controlled clinical trial.

Sixty patients scheduled for a spine surgery will be randomly assigned to two groups. Lidocaine group will receive an intravenous bolus injection of lidocaine 1.5 mg/kg before intubation, followed by 2 mg/kg/h continuous infusion during the operation. Placebo group will receive the same dosage of saline at the same time. Analgesic requirement will be monitored using patient-controlled Analgesia (PCA protocol: demand dose is 2 mg of morphine, lockout 5 min, maximum dose 15 mg per hour). Forty-eight hours after surgery, we will check the morphine consumption in two groups. Quality of recovery after surgery will be assessed using Q0R15 questionnaire.
BACKGROUND: Azvudine, a repurposed oral small molecule antiviral drug, has potential effects in combating the SARS-CoV-2 virus. However, studies on its clinical efficacy in patients with COVID-19 are still limited and controversial, and further research and validation are necessary.
METHODS: A retrospective cohort study was conducted on COVID-19 patients who were hospitalized in the General Hospital of Central Theater Command from 1 December 2022 to 31 January 2023. We included 132 patients treated with Azvudine and 132 controls after screening and propensity score matching. The primary outcomes including all-cause mortality and a composite outcome of disease progression such as non-invasive respiratory support, invasive respiratory support, admission to intensive care unit (ICU), and death were compared.
RESULTS: Azvudine recipients had a much lower incidence rate of composite disease progression outcome than controls (13.9075/1000 person-days versus 25.7731/1000 person-days, P<0.05). Azvudine recipients also possessed a lower all-cause mortality rate than controls (2.6797/1000 person-days versus 8.5910/1000 person-days, P<0.01). Azvudine treatment significantly reduced the risk of composite disease progression (HR: 0.37, 95% CI: 0.16-0.84, P=0.017) and all-cause death (HR: 0.25, 95% CI: 0.08-0.81, P=0.021) after adjusting potential confounding factors such as age, sex, severity of COVID-19, complications, concomitant therapy, time from symptoms to treatment, and important laboratory indicators. The subgroup analyses of composite disease progression outcome and all-cause death indicated robustness of Azvudine's in treating COVID-19 patients in general.
CONCLUSION: Our study demonstrates that Azvudine has a significant positive impact on the clinical recovery of hospitalized patients with COVID-19. These findings provide important support for the use of Azvudine as a therapeutic option for COVID-19, given the current divergent views on its therapeutic efficacy and its importance in public health and medical care.
Antibodies are disclosed which bind specifically to P-selectin and which block the binding of PSGL-1 to P-selectin. These anti-P-selectin antibodies may also cause dissociation of preformed P-selectin/PSGL-1 complexes. The disclosure identifies a heretofore unrecognized, near N-terminal, antibody binding domain (a conformational epitope) of P-selectin to which the function-blocking antibodies (which may be chimeric, human or humanized antibodies for example) bind. Antibodies are disclosed which bind to the conformational epitope of P-selectin and which have a dual function in blocking binding of PSGL-1 to P-selectin, and in causing dissociation of preformed P-selectin/PSGL-1 complexes. Such single and dual function anti-P-selectin antibodies and binding fragments thereof may be used in the treatment of a variety of inflammatory and thrombotic disorders and conditions. Screening methods for identifying such antibodies are also disclosed.
Patients allocated to the intervention group will receive 1x1010 colony forming units (CFU) of L. rhamnosus GG (Culturelle, Locin Industries Ltd) in 1 capsule suspended in tap water, administered through a nasogastric (or orogastric) or nasoduodenal (or oroduodenal) tube twice daily while patients are in the ICU. The first dose will be within 72 hours of intubation. Patients in the ICU who await discharge and can swallow pills will take the capsules orally.
One IVT injection of aflibercept 2 mg at Baseline, Week 4, and Week 8, with one IVT insertion of AR-14034 SR higher dose at Week 6. Up to one retreatment of AR-14034 SR will be administered between Weeks 16 and 52 according to protocol-specified disease activity criteria. Sham procedures will be performed between Weeks 16 and 52 except when AR-14034 SR repeat treatment is administered.
An unswollen UV cross-linked chitosan injectable hydrogel and a synthesis method thereof. The invention belongs to the field of biopolymer material synthesis and modification. The invention aims to solve the problem that the existing UV cross-linked chitosan hydrogel has high swelling degree, so that surrounding tissues can be extruded at an implanted part. The hydrogel is formed by UV crosslinking of N-amylene chitosan, a water-based medium and a photoinitiator. The synthesis method comprises the following steps: dissolving N-pentenyl chitosan in an aqueous medium to obtain an aqueous solution of the N-pentenyl chitosan; secondly, adding a photoinitiator into the aqueous solution of the N-pentenyl chitosan obtained in the first step, and placing the aqueous solution of the N-pentenyl chitosan under UV irradiation for crosslinking to form hydrogel. The invention utilizes acylation reaction between chitosan and pentenoic anhydride to synthesize N-pentenyl chitosan by one-step method, the length of carbon chain formed by UV crosslinking of pentenyl unit is 10 strong hydrophobic units, the non-swelling property of hydrogel is endowed, and the swelling degree is only 0.6-0.8 times.
CARBOCAINE stabilizes the neuronal membrane and prevents the initiation and transmission of nerve impulses, thereby effecting local anesthesia.

CARBOCAINE is rapidly metabolized, with only a small percentage of the anesthetic (5 to 10 percent) being excreted unchanged in the urine. CARBOCAINE because of its amide structure, is not detoxified by the circulating plasma esterases. The liver is the principal site of metabolism, with over 50 percent of the administered dose being excreted into the bile as metabolites. Most of the metabolized mepivacaine is probably resorbed in the intestine and then excreted into the urine since only a small percentage is found in the feces. The principal route of excretion is via the kidney. Most of the anesthetic and its metabolites are eliminated within 30 hours. It has been shown that hydroxylation and N-demethylation, which are detoxification reactions, play important roles in the metabolism of the anesthetic. Three metabolites of mepivacaine have been identified from adult humans: two phenols, which are excreted almost exclusively as their glucuronide conjugates, and the N-demethylated compound (2', 6' - pipecoloxylidide).

The onset of action is rapid (30 to 120 seconds in the upper jaw; 1 to 4 minutes in the lower jaw) and CARBOCAINE 3% injection will ordinarily provide operating anesthesia of 20 minutes in the upper jaw and 40 minutes in the lower jaw.

CARBOCAINE 2% with Neo-Cobefrin 1:20,000 injection provides anesthesia of longer duration for more prolonged procedures, 1 hour to 2.5 hours in the upper jaw and 2.5 hours to 5.5 hours in the lower jaw.

CARBOCAINE does not ordinarily produce irritation or tissue damage.

Neo-Cobefrin is a sympathomimetic amine used as a vasoconstrictor in local anesthetic solutions. It has pharmacologic activity similar to that of Epinephrine but it is more stable than Epinephrine. In equal concentrations, Neo-Cobefrin is less potent than Epinephrine in raising blood pressure, and as a vasoconstrictor.
BACKGROUND: This study presented the new Life's Essential 8 (LE8) framework for examining cardiovascular health (CVH) to analyze the potential relationship between the latter and hyperuricemia (HUA) in the U.S. population.
METHODS: Data on individuals aged at least 20 years were collected from the National Health and Nutrition Examination Survey (NHANES) 2009-2020. Smoothed curve fitting and multivariate logistic regression analyses were then performed on a sample of 25,681 adults to explore the association between LE8 and HUA. A sensitivity analysis was conducted to examine the robustness of the research findings.
RESULTS: The study found a strong negative association between LE8 and HUA, with an odds ratio (OR) of 0.71 and a 95% confidence interval (CI) from 0.69 to 0.73 after adjusting for multiple confounding factors. The sensitivity analysis further validated the robustness of this association. This analysis consistently showed negative associations across different genders, ages, races, and education levels (p < 0.05), but there were no significant relationships with marital status. The association between uric acid levels and LE8 displayed an inverted L-shaped curve, with an inflection point around 41.43.
CONCLUSIONS: The findings indicate a strong negative relationship between LE8 and HUA among the U.S. population, suggesting that higher scores on the LE8, which assesses CVH, were associated with reduced uric acid levels. The consistent negative association underscores the LE8 framework's potential as a valuable tool for understanding and managing HUA in CVH.
MRG-001 will be administered subcutaneously at 0.007 mL/kg. Patients will receive 3 injections per week every other day for a total of 2 weeks or until discharge from the ICU.
The life span in patients with Duchenne muscular dystrophy has been extending due to the development of artificial respiratory devices. According to that, the ratio of cardiac dysfunction as a cause of death has been increasing. This cardiac dysfunction was associated with minor cardiac damage as indicated by elevation of plasma cardiac troponin I (cTnI). Furthermore, and the detection rate of cTnI plasma as revealed to be correlated with the deterioration speed of LV dysfunction assessed by serial echocardiography measurements. Accordingly, if this minor cardiac damage is suppressed, it is postulated that the progression of cardiac dysfunction can be stopped. In the cases with ventricular arrhythmia and tachycardia, we found plasma cTnI became undetectable after administration of beta-blocker. Accordingly, we investigate whether administration of beta-blocker, carvedilol can persistently suppress the minor cardiac damage and lead to suppress the deterioration of LV function. Note that his study preventive study for preserved to moderate LV dysfunction and is not intended to the beta-blocker treatment for severe LV dysfunction. Because we assume that the mechanism of elevation of cTnI is different; spontaneous in preserved to mild LV dysfunction in patients but LV wall stress in severe LV dysfunction in patients with Duchenne muscular dystrophy.